Devices keeps track of blood sugar levels to automatically adjust and deliver insulin doses.
Two new devices are available for people with type 1 diabetes that can automatically deliver insulin using technology according to blood sugar levels:
Hybrid system self-adjusting insulin pump automatically adjusts insulin dose for people with type 1 diabetes
A new self-adjusting insulin pump system is available now for people with type 1 diabetes that can deliver insulin as and when needed.
The ‘hybrid’ technology aims to reduce the burden for people living with type 1 diabetes in keeping track of blood sugar readings.
The MiniMed 670G by Medtronic is a hybrid closed loop (HCL) insulin pump - ‘hybrid’ the user can still interact with the technology as required to enter figures for carbohydrate and corrections.
The insulin pump features a SmartGuard Auto Mode that can automatically adjust doses of basal insulin every five minutes to meet the individual needs of the person with type 1 diabetes. This can keep the person within a healthy glucose range and help reduce blood sugar level highs and lows and risk of additional health complications, such as hypoglycaemia.
Hypoglycaemia, also known as a hypo, happens when blood sugar levels of people with diabetes drop too low and they can feel shaky, unwell and, in serious cases, can slip into a coma.
The pump system was designed to make living with type 1 diabetes easier and reduce the burden of self-managing the condition.
The closed loop system uses readings from a continuous glucose monitor (CGM) sensor, to instruct the pump to not only deliver insulin when blood sugar readings are high, but also to suspend insulin delivery if readings are low.
Patch pump system available that could enable independent type 1 diabetes management
A micro insulin pump is available now in Europe that combines continuous glucose monitoring (CGM) (via the Dexcom G6 device) to calculate the amount of insulin required for people with type 1 diabetes – to automatically adjust delivery of insulin through a Kaleido pump.
Michael Graves, CEO of ViCentra, said: “The promising results from the launch of our Kaleido insulin patch pump in the Netherlands has confirmed that we’re filling a gap in the insulin pump market. Our team has developed a unique and innovative product that addresses a very real need for choice, discretion and simplicity in the insulin pump market. We believe in a future where closed loop systems will become a part of diabetes management and we believe that Kaleido can be an important part of this.”
Erik Huneker, founder and co-CEO of Diabeloop added: “DBLG1 System is a true revolution, decreasing the burden of managing type 1 diabetes while lowering both time spent in hypoglycemia and the risk of complications. Combined with the size, convenience and reliability of the Kaleido pump, it will give back freedom and peace of mind to people living with type 1 diabetes.”